Bicalutamide Capsules Application Scope

Bicalutamide is indicated for use in combination with a luteinizing hormone-releasing hormone (LHRH) analogue for the treatment of Stage D2 metastatic prostate cancer.

bicalutamide capsules

Characteristics of Bicalutamide Capsules

Ingredient: Bicalutamide, a non-steroidal anti-androgen.

Characteristics: Used in combination with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of advanced prostate cancer.

Specification: Each tablet contains 50 mg of bicalutamide.

Packing Specification: Typically available in blister packs or bottles; specific packaging may vary by manufacturer.

Storage: Store at controlled room temperature, 20°C to 25°C (68°F to 77°F). Protect from light and moisture.

Expiry Date: Typically 24 months from the date of manufacture; refer to the packaging for exact expiry date.

Manufacturer: Various manufacturers produce bicalutamide; refer to the packaging for specific manufacturer information.

Bicalutamide Capsules Directions for Use

Dosage and Administration: The recommended dose is one 50 mg tablet once daily, taken at the same time each day, either in the morning or evening, with or without food. Treatment with bicalutamide should be started at the same time as treatment with an LHRH analog.

Adverse Reactions: Common side effects include hot flashes, pain, asthenia, constipation, infection, nausea, peripheral edema, dyspnea, and diarrhea. Gynecomastia and breast tenderness may also occur.

Dosage Restrictions

Contraindications: Bicalutamide is contraindicated in patients with hypersensitivity to the drug or any of its components. It is also contraindicated in women, particularly those who are or may become pregnant.

Precautions: Liver function tests should be performed at regular intervals due to the potential for hepatic changes. Bicalutamide should be used with caution in patients with moderate to severe hepatic impairment.

Bicalutamide Capsules Interactions

Caution is advised when bicalutamide is co-administered with medications metabolized by cytochrome P450 enzymes, as bicalutamide may inhibit these enzymes, potentially leading to increased plasma concentrations of such drugs.

Note: If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYueMedicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.